Sareum Holdings PLC (FRA:RYH0)

Half Year 2026 Sareum Holdings PLC Earnings Call Transcript

Mar 12, 2026 / 02:00 PM GMT

Release Date Price: €0.128

Transcript

Key Points

Positve

Sareum Holdings PLC (STU:RYH0) has restarted the phase two enabling toxicology program for SDC 1,801 with a new CRO, showing commitment to advancing their pipeline.
The company has a strong safety profile for SDC 1,801, with no black box warnings, which is promising for its development in autoimmune diseases.
Sareum Holdings PLC (STU:RYH0) has completed the manufacture of a GMP batch of SDC 1,801, ready for clinical trials, indicating preparedness for the next phase.
The company is actively seeking partnerships for SRA 737, with an extended IP and an active IND in the US, enhancing its attractiveness to potential partners.
The collaboration with receptor.AI for CNS diseases is progressing well, with a second batch of compounds in synthesis, showing ongoing innovation and expansion into new therapeutic areas.

Negative

The previous study for SDC 1,801 had to be discontinued due to unexpected findings, setting back the program by about six months.
There is uncertainty regarding the outcome of the ongoing toxicology study for SDC 1,801, as it is still in progress and subject to unknowns.
The company faces challenges in securing compensation for the previous study's issues, as pursuing legal action against the CRO is deemed not cost-effective.
Sareum Holdings PLC (STU:RYH0) has experienced delays and unexpected results in their programs, which may affect investor confidence.
The commercialization strategy for the TI 2 neuroscience program is still in early stages, with no clear timeline for securing out-licensing deals.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SAR.L - Sareum Holdings PLC
Half Year 2026 Sareum Holdings PLC Earnings Call
Mar 12, 2026 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to the Cyre Holdings PLC Interim Results Investor presentation. Throughout this recorded presentation, investors will be in listen-only mode. Questions are encouraged and they can be submitted at any time using the Q&A tab situated on the right hand corner of your screen. Just simply type in your questions and press send. Before we begin, I would like to submit the following poll, and I would now like to hand you over to executive Chairman, Doctor Stephen Parker. Good afternoon to you, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Hello and

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.